Sengenics | Autoantibody Biomarker | Proteomic Technology

Antibody Biomarkers are Transforming Cancer Research
Get your FREE white paper to find out how!

Cancer’s complexity and diversity create a critical demand for biomarkers that advance early diagnosis and predict treatment response for improved patient survival.

Navigate the future of oncology with our white paper, “Autoantibodies: Powerful Biomarkers in Cancer Precision Medicine.”

Discover:

How cancer can elicit the production of autoantibodies by our immune system years before clinical diagnosis

How an autoantibody signature paints a more complete picture of cancer than genetics and imaging alone

The transformative role autoantibody biomarkers play in personalized medicine

"*" indicates required fields

First Name*

Last Name*

Email*

Organization*

City*

Country*

Research Field (Check all that apply)*

Cardiology

Immunology

Neurobiology

Oncology

Other

Research Sector*

Currently conducting biomarker research?*

By proceeding, I agree to Sengenics’ Terms of Use and acknowledge that I have read the Privacy Policy.

I also agree that Sengenics or its representatives may contact me by email at the email address I provide, including for marketing purposes.

Comments

This field is for validation purposes and should be left unchanged.

Cancer biomarker discovery

Sengenics KREX technology measures antibody biomarkers with industry-leading precision

Disease detection | Tailored treatments | Outcome prediction | Disease endotyping | Patient stratification

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline.

Design and development by RainCastle Communications.

Cancer biomarker discovery

Fill in the form to download the publication

Watch the video

Watch the video

Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation

Read the Review

Watch the video